Experiment Recreates The Universe's Very First Chemical Reactions
A team of physicists Led by Florian Grussie of the Max Planck Institute for Nuclear Physics (MPIK) in Germany has reproduced the reactions of helium hydride ion (HeH+), a molecule made from a neutral helium atom fusing with an ionized atom of hydrogen.
These are the first steps that lead to the formation of molecular hydrogen (H2); the most abundant molecule in the Universe and the stuff from which stars are born. The new work, therefore, elucidates some of the earliest processes that gave rise to the Universe as we know it today.
Related: The First Molecular Bond in The Universe Has Finally Been Detected in Space
The birth throes of the Universe some 13.8 billion years ago produced a hot, dense soup of fundamental particles simmering at temperatures too high for atoms to form.
It took about 380,000 years for nuclei and electrons to lose enough energy to congeal into the very first elements. Those elements were the lightest the periodic table has to offer; about 75 percent hydrogen, 25 percent helium, and trace amounts of lithium.
Hydrogen continues to dominate the Universe's ingredient list today, as clouds of molecular gas that give birth to the stellar furnaces from which the heavier elements are born, either through fusion or violent explosions.
None of that, however, could happen without HeH+ – a molecule that scientists believe played a huge role in cooling the Universe enough so that the molecular clouds could contract enough to attain the density required to collapse under their own gravity to form the seeds of baby stars.
That's because HeH+ has a comparatively large separation between its positive and negative charges. In the presence of an electric field, a molecule with a large charge separation undergoes an energy shift that helps dissipate heat, which means HeH+ theoretically played a key role in paving the way for the formation of the first stars.
The researchers performed their experiments at the Max Planck Institute's Cryogenic Storage Ring, a facility designed to perform experiments in a vacuum environment at temperatures just a few degrees above absolute zero, around -267 degrees Celsius (-449 Fahrenheit), mimicking the conditions of deep space.
There, they carefully studied interactions between HeH+ and a hydrogen atom with one extra neutron in its nucleus, known as deuterium. An interaction between HeH+ and deuterium generates a neutral helium atom and a molecule consisting of one neutral hydrogen atom and one charged deuterium atom (HD+), with lower energy levels than the original components.
Within the storage ring, the researchers fired two beams of particles; one with HeH+ molecules, the other with neutral deuterium. They changed the speed of the two beams to alter the energy at which the particles collided as a proxy for temperature to see if temperature played a role in the reaction rate.
It did not. The rate at which the reaction took place remained steady, regardless of the proxy temperature – suggesting that the role HeH+ played in the early Universe did not decline as cooling unfolded, and that its role in the formation of the first generation of stars was a significant one.
"Previous theories predicted a significant decrease in the reaction probability at low temperatures, but we were unable to verify this in either the experiment or new theoretical calculations by our colleagues," physicist Holger Kreckel from the MPIK explains.
"The reactions of HeH+ with neutral hydrogen and deuterium therefore appear to have been far more important for chemistry in the early Universe than previously assumed."
The research has been published in Astronomy & Astrophysics.
Related News
Scientists Just Admitted Nobody Really Gets Quantum Physics
First Quantum Bit Made of Antimatter Captured in Physics Breakthrough
Gold Does Something Unexpected When Superheated Past Its Melting Point
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
2 minutes ago
- Forbes
2 Reasons We Feel Better When Others Are Worse Off — By A Psychologist
Most of us have a natural tendency to compare ourselves to others. This can be explained by social comparison theory, developed by psychologist Leon Festinger, which suggests that we determine our self-worth by comparing ourselves to others. When others experience setbacks, we may experience a range of emotions in response, from empathy to pity to even joy at their misfortune. While feeling happy about someone else's pain may sound strange, it's not as uncommon as you might think. This stems from our tendency for 'downward social comparison.' When we compare downward — i.e., to someone worse off — we often feel better about our own lives. It's a subtle, sometimes unconscious coping mechanism, especially in moments of self-doubt. The emotional experience of pleasure in response to another's misfortune is called Schadenfreude, a German word that combines Schaden, which means 'damage,' and Freude, which means 'joy.' Schadenfreude often occurs in competitive environments. For instance, you may feel happy when an employee who cozies up to your boss performs poorly and gets berated by them. This is because people have an inherent need to feel better about themselves and often acquire a better self-image by comparing themselves to others who may be less fortunate. Consequently, people who feel their self-worth is threatened are more likely to feel Schadenfreude. Here are two key reasons why you may be feeling happy about somebody else's suffering: 1. Schadenfreude May Boost Self-esteem In Competitive Scenarios Why do we feel a sense of guilty pleasure at someone's downfall? In a 2017 study published in the European Journal of Social Psychology, researchers sought to answer this question. They tested whether Schadenfreude met any of these four basic psychological needs: the need for self-esteem, control, belongingness and a meaningful existence. Researchers conducted four experiments, all of which pointed to similar outcomes: Schadenfreude does meet our basic need to reaffirm our social standing through comparisons, especially when we compare ourselves to a rival we're envious of. In the first study, participants were asked to imagine being in a job interview, which was also being attended by their primary university competitor. They were told that only one would get the position. In the competitive scenario, participants felt more schadenfreude and need satisfaction than in non-competitive circumstances. Researchers found that they felt more in charge, experienced higher self-esteem and felt a greater sense of belonging. In another situation, they were asked to recall a real-time scenario when their competitor failed. Once again, researchers found that more schadenfreude led to increased feelings of self-esteem, a greater sense of personal control and a stronger perception of meaning in life. Seeing someone else fail or struggle can shield us from feelings of inadequacy, at least for the time being. When life feels out of control, seeing others in similar or worse positions makes our own experiences feel less like personal failures and more like part of a shared human messiness. This is especially true in more competitive scenarios. We all want to believe we're doing 'okay' in life. If someone else is doing worse than us, it affirms that we're not falling behind. 2. Schadenfreude May Reaffirm Your Belief In A Just World Interestingly, another 2013 study published in the Australian Journal of Psychology found a link between schadenfreude and beliefs in a 'just' world. When people's belief in a just world was threatened, they felt more pleasure when someone else suffered a misfortune. For example, they might laugh more at a story where someone 'gets what they deserve.' This may be because they want to restore their belief that the world is fair. When someone holds such beliefs, they're more likely to think that good things happen to good people, while misfortune finds those who deserve it. If they can't help the victim, they might instead blame the victim or believe the person deserved it. This way, they get to justify the misfortune that befell them. However, this does not always indicate that the victim is deserving of punishment or that they are responsible for the outcome. Does Schadenfreude Make You A Bad Person? Schadenfreude doesn't automatically make you a terrible human being. The practice of downward comparison may feel cruel, but that is not always the intention. These reactions often happen without our conscious awareness, and you may have tried to push these thoughts away, knowing it wasn't right. This sense of awareness and moral grounding is what differentiates you from someone that deliberately wants to watch others fail. However, if you find yourself constantly hoping for someone else's downfall and actively trying to put them in compromising situations, that may be worrisome. Instead of trying to eliminate the instinct entirely, try to notice it but avoid giving it too much power. Otherwise, it may make you complacent and feel less motivated to improve because you think 'at least, I'm not that bad.' If you must compare, try to shift your mindset to lateral or upward comparisons that inspire change. Try to put in effort to grow. Look at people doing 'better' than you and learn from them. If seeing others do better than you makes you feel like you're 'not enough' or that you haven't 'achieved enough,' try comparing yourself to those only one or two steps ahead of you. That way, you can realistically map out your progress. You may also want to mark your progress against your past self. Self-comparison allows you to see how far you've come and where you want to go from here, but like any form of comparison, it's a double-edged sword that can make you spiral about your flaws. The healthiest approach is to learn to accept yourself right where you are, without any sense of comparison, viewing your journey in this life as strictly your own. When you begin to embrace the feeling of being and having 'enough,' you naturally stop engaging in self-destructive behaviors or trying to bring others down. Do you often take pleasure in others' misfortune to make yourself feel better? Take this science-backed test to find out: The Schadenfreude Scale
Wall Street Journal
2 hours ago
- Wall Street Journal
‘Battle of the Big Bang' Review: A Question of Origins
In the 1920s, scientists discovered that the universe was not static in size, as had previously been assumed, but was expanding in all directions. Galaxies were rushing away from one another as the very space between them was stretching. It was tempting, therefore, to imagine running the film backward into the past. The expansion, it seemed, must have started somewhere: at an infinitely hot, infinitely small and infinitely dense point from which everything exploded some 13.8 billion years ago. This origin became known as the big bang, and that infinitely small point at which it all began was called a singularity: a place where all the known laws of physics break down. Time was purportedly created only at the moment of banging, so it made no sense to ask what came before the big bang, just as it makes no sense to ask what is north of the North Pole. Why it happened at all remained an awkward question, but the existence of such an inscrutable singularity at the birth of all things became the mainstream view. It might be surprising, then, to learn that few experts in the field hold this view anymore. The traditional picture of the big bang is actually two separate ideas, explain Niayesh Afshordi and Phil Halper in 'Battle of the Big Bang: The New Tales of Our Cosmic Origins.' Researchers continue to endorse the hot big bang, the idea of a primordial explosion of energy, but most do not think it goes back to 'a state of infinite density where time stands still and the answers to all our origin questions meet their demise.' Mr. Afshordi is a professor of physics and astronomy at the University of Waterloo in Canada; Mr. Halper is a fellow of the Royal Astronomical Society and the creator of the YouTube series 'Before the Big Bang.' Their excellent book promises to map the 'quiet revolution' of 21st-century cosmology and introduce us to the revolutionaries. In very different ways, these rebels are all addressing questions left unanswered by the old theory. One is the origin-of-structure problem: The big bang ought to have spread energy homogeneously throughout space, but we observe clumps of galaxies with vast spaces between them, and measurements of the cosmic microwave background—the fossil radiation from when the universe was only 380,000 years old—reveal an unpredictable pattern of warm and cold spots. Nor have we ever seen an inflaton, a hypothetical particle that is supposed to have driven a period of enormous growth in the size of the early universe.
Yahoo
5 hours ago
- Yahoo
Cell Line Development Market Outlook Report 2025-2034: PromoCell, Novartis, Genscript Biotech, Sartorius, and Thermo Fisher Scientific Dominate the Industry
Booming Biologics and Biosimilars Market Drives Global Cell Line Development Surge; CDMOs and Technological Advancements Key to Growth Cell Line Development Market Dublin, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The "Cell Line Development Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" has been added to offering. The Global Cell Line Development Market was valued at USD 7.5 billion in 2024 and is estimated to grow at a CAGR of 10.2% to reach USD 19.7 billion by 2034. Market expansion is being fueled by a growing focus on biologics and biosimilars, particularly as the pharmaceutical industry shifts toward personalized therapies and precision medicine. The surge in demand for monoclonal antibodies, vaccines, and recombinant proteins has placed strong emphasis on the development of highly stable and productive cell lines. The increase in chronic illnesses-such as autoimmune diseases, cancer, and infectious disorders-has led to the rising adoption of biologics, which depend heavily on well-characterized cell lines. This has also elevated the need for quality-controlled production systems. Contract development and manufacturing organizations (CDMOs) have contributed significantly to market momentum. Small and mid-sized biotech firms are increasingly outsourcing their cell line development to CDMOs to reduce overhead costs and accelerate timelines, benefiting from their technical expertise, scalable platforms, and regulatory compliance with agencies like the FDA. This trend allows companies to focus on core competencies such as research and innovation while leveraging CDMOs for end-to-end services including cell line screening, clone selection, process optimization, and GMP manufacturing. These partnerships also offer access to advanced technologies, streamlined workflows, and proven quality assurance frameworks, enabling faster entry into clinical trials and reducing risks associated with internal capacity limitations. The reagents and media segment generated USD 3.4 billion in 2024. This segment continues to dominate due to its central role in cell growth and maintenance across both R&D and production stages. With a notable increase in the use of mammalian cells for biologics manufacturing, the demand for high-efficiency reagents and cell culture media has surged. A growing preference for protein-free and serum-free media is helping the segment gain traction, offering improved scalability, reduced risk of contamination, and consistency in large-scale production environments. Such media types are essential for regulatory approval and efficiency in biologics manufacturing, which demands stringent process control. In terms of cell type, the mammalian cells segment generated the highest revenue in 2024, accounting for 71.4%. Their dominance is linked to their superior ability to express human-compatible therapeutic proteins with accurate post-translational modifications. Widely used cell lines such as CHO and HEK-293 are favored in biologics production due to their robust protein folding, glycosylation, and scalability. Technological progress in gene editing tools, such as CRISPR-Cas9, combined with automation and high-throughput systems, continues to enhance the speed and stability of mammalian cell line development, further reinforcing their leadership in the market. The United States Cell Line Development Market was valued at USD 2.6 billion in 2024, driven by a combination of advanced biopharma infrastructure, high rates of chronic disease, and strong adoption of cutting-edge biologic therapies. The country's well-established pharmaceutical ecosystem, which includes top-tier biotech firms and extensive R&D investment, plays a pivotal role in expanding the market. Research institutions and innovation hubs across the US are also accelerating technological advancements in gene editing and automated platforms, leading to faster and more efficient development cycles. Government and private sector funding are also propelling innovation, further supporting the country's leadership in the field. Key companies operating in the Global Cell Line Development Market include PromoCell, Novartis, Genscript Biotech, Sartorius, Thermo Fisher Scientific, ProBioGen, Cytiva (Danaher Corporation), ASIMOV, Advanced Instruments, Sigma Aldrich (Merck KGaA), Eurofins Scientific, WuXi AppTec, Aragen Life Sciences, Fyonibio, and Lonza Group. Top-tier players in the cell line development space are heavily investing in technological innovations like automated cell screening platforms, single-use bioreactors, and CRISPR-based genome editing. Many companies are forming strategic alliances with biotech firms and CDMOs to enhance service offerings and expand production capabilities. Acquisitions are also a popular move to integrate novel technologies or gain regional access. Firms are focusing on R&D to develop serum-free and chemically defined media, helping improve regulatory compliance and scalability. Comprehensive Market Analysis and Forecast Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape Competitive landscape with Porter's Five Forces and PESTEL analysis Market size, segmentation, and regional forecasts In-depth company profiles, business strategies, financial insights, and SWOT analysis Key Attributes Report Attribute Details No. of Pages 145 Forecast Period 2024-2034 Estimated Market Value (USD) in 2024 $7.5 Billion Forecasted Market Value (USD) by 2034 $19.7 Billion Compound Annual Growth Rate 10.2% Regions Covered Global Key Topics CoveredChapter 1 Methodology and ScopeChapter 2 Executive Summary2.1 Industry 360 synopsis2.2 Key market trends2.2.1 Regional2.2.2 Products & services2.2.3 Source2.2.4 Cell line2.2.5 Application2.2.6 End use2.3 CXO perspectives: Strategic imperatives2.3.1 Key decision points for industry executives2.3.2 Critical success factors for market players2.4 Future outlook and strategic recommendationsChapter 3 Industry Insights3.1 Industry ecosystem analysis3.1.1 Supplier landscape3.1.2 Value addition at each stage3.1.3 Factors affecting the value chain3.2 Industry impact forces3.2.1 Growth drivers3.2.1.1 Growing vaccine production worldwide3.2.1.2 Increasing prevalence of cancer across the globe3.2.1.3 Technological innovations in cell line development3.2.1.4 Growing biotechnology industry3.2.2 Industry pitfalls and challenges3.2.2.1 Complex regulatory landscape3.2.2.2 Challenges related to stem cell research3.2.3 Market opportunities3.2.3.1 Emerging applications in personalized medicine and regenerative therapies3.2.3.2 Adoption of artificial intelligence in cell line optimization3.3 Growth potential analysis3.4 Regulatory landscape3.4.1 North America3.4.2 Europe3.4.3 Asia Pacific3.4.4 Latin America3.4.5 Middle East and Africa3.5 Future market trends3.6 Emerging therapeutic applications of CHO cell lines3.7 Technology landscape3.7.1 Current technological trends3.7.2 Emerging technologies3.8 Porter's analysis3.9 PESTEL analysisChapter 4 Competitive Landscape, 20244.1 Introduction4.2 Company market share analysis4.3 Company matrix analysis4.4 Competitive analysis of major market players4.5 Competitive positioning matrix4.6 Key developments4.6.1 Merger and acquisition4.6.2 Partnership and collaboration4.6.3 New product launches4.6.4 Expansion plansChapter 5 Market Estimates and Forecast, By Products & Services, 2021 - 2034 ($ Mn)5.1 Key trends5.2 Reagents and media5.3 Equipment5.3.1 Incubator5.3.2 Centrifuges5.3.3 Bioreactors5.3.4 Storage equipment5.3.5 Microscopes5.3.6 Electroporators5.3.7 Fluorescence-activated cell sorting5.3.8 Other equipment5.4 Accessories and consumables5.5 ServicesChapter 6 Market Estimates and Forecast, By Source, 2021 - 2034 ($ Mn)6.1 Key trends6.2 Mammalian6.2.1 Chinese Hamster Ovary (CHO)6.2.2 Human Embryonic Kidney (HEK)6.2.3 Baby Hamster Kidney (BHK)6.2.4 Murine myeloma6.2.5 Other mammalian sources6.3 Non-mammalian6.3.1 Insects6.3.2 AmphibiansChapter 7 Market Estimates and Forecast, By Cell Line, 2021 - 2034 ($ Mn)7.1 Key trends7.2 Recombinant7.3 Hybridomas7.4 Continuous cell lines7.5 Primary cell linesChapter 8 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)8.1 Key trends8.2 Bioproduction8.3 Drug discovery8.4 Toxicity testing8.5 Tissue engineering8.6 ResearchChapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)9.1 Key trends9.2 Pharmaceutical and biotechnology companies9.3 Academic and research institutes9.4 Contract research organizations (CROs)Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)10.1 Key trends10.2 North America10.2.1 U.S.10.2.2 Canada10.3 Europe10.3.1 Germany10.3.2 UK10.3.3 France10.3.4 Italy10.3.5 Spain10.3.6 Netherlands10.4 Asia Pacific10.4.1 China10.4.2 Japan10.4.3 India10.4.4 Australia10.4.5 South Korea10.5 Latin America10.5.1 Brazil10.5.2 Mexico10.6 Middle East and Africa10.6.1 South Africa10.6.2 Saudi Arabia10.6.3 UAEChapter 11 Company Profiles11.1 Advanced Instruments11.2 Aragen Life Sciences11.3 ASIMOV11.4 Cytiva (Danaher Corporation)11.5 Eurofins Scientific11.6 Fyonibio11.7 Genscript Biotech11.8 Lonza Group11.9 Novartis11.10 ProBioGen11.11 PromoCell11.12 Sartorius11.13 Sigma Aldrich (Merck KGaA)11.14 Thermo Fisher Scientific11.15 WuXi AppTecFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cell Line Development Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
